Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab versus placebo in active non-radiographic axial spondyloarthritis
NL-OMON55386Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-radiographic axial spondyloarthritis (nr-axSpA) comparing Bimekizumab 160 mg Q4W with Placebo Q4W (2 arms). Primary endpoint: ASAS40 response at Week 16. Started Jan 2020; status: active, not recruiting.
02
Drugs
bimekizumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON55386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55386.